Expert Interviews

The future of obesity medicine is filled with promise as GLP-1 RAs and other peptides continue to demonstrate pluripotency in metabolic disease.

Agitation affects at least one half of adults with Alzheimer disease; geriatric psychiatrist Grossberg explains the symptoms and new treatments in this year's video series.

Donna Ryan, MD, highlights exciting advancements in weight loss and metabolic treatments, particularly involving GLP-1 RAs and related therapies.

The new nonsteroidal topical treatments for atopic dermatitis are targeted and modify the disease process, explains thought leader Shahriari in this year's video series.

The GOLD report committee member highlights advances in knowledge of COPD phenotypes and the new role for biologic medications in this year's video series.

Hopkins, of the National Foundation for Infectious Diseases, is frustrated by the diminished societal response to the virus' circulation including ongoing low vaccination rates.

Donna Ryan, MD, highlights how the media has helped to reframe obesity as a chronic disease and how antiobesity drugs are transforming metabolic disease treatment.

Donna Ryan, MD, discusses the most significant clinical trials published this year in the field of obesity medicine.

Panelists discuss key insights on the importance of early screening for T1D, the role of antibody testing in identifying at-risk individuals, and the need for timely intervention to preserve ß-cell function and optimize long-term management strategies for better patient outcomes.

Panelists discuss how teplizumab infusion requires specialized medical facilities equipped to manage intravenous therapy, monitor for potential adverse effects, and provide appropriate care during treatment to ensure patient safety and efficacy.